BIOLIDICS LIMITED

(Company Registration Number: 200913076M)

RESPONSE TO QUESTIONS RECEIVED FROM SHAREHOLDERS AND SIAS PRIOR TO THE COMPANY'S ANNUAL GENERAL MEETING AND EXTRAORDINARY GENERAL MEETING

Questions from shareholders

1. Are we currently applying with Indonesian authorities for the use of Covid-19 test kit in Indonesia?

Company's response: The Company has not submitted any application to the Indonesian authorities for the use of its test kits for the detection of SARS-CoV-2 antibodies in human serum, plasma and whole blood (the "**COVID-19 Antibody Test Kits**") in Indonesia. The Company will provide timely updates to shareholders whenever there are material developments in Indonesia and in other markets.

2. It is noted that CK has been assigned as the distributor of the test kits? Have we got HK approval for the use of these kits?

Company's response: As disclosed in the announcement on 15 April 2020, CK Life Sciences Int'l., Inc ("**CK**") was appointed as a non-exclusive distributor of the COVID-19 Antibody Test Kits, in the Hong Kong Special Administrative Region ("**Hong Kong**"). The provisional authorisation granted by the Health Sciences Authority of Singapore (announced on 30 March 2020) allows the Company's COVID-19 Antibody Test Kits to be exported out of Singapore subject to the duties and obligations as stipulated in the Health Products Act and the Health Products (Medical Devices) Regulation 2010. The Company understands that under the regulatory regime of Hong Kong, the test kits do not need to be approved but may only be used by a licensed qualified personnel in a healthcare institution setting in Hong Kong.

3. What are the plans for manufacture and scaling up production of the test kits?

Company's response: The Company's plans for manufacturing and scaling up production of the test kits would depend very much on the demand for the COVID-19 Antibody Test Kits. As previously announced, the Company had entered into a manufacturing agreement for the COVID-19 Antibody Test Kits on 21 March 2020. The Company is actively developing the market for the test kits in Singapore, the Philippines, the European Union as well as the United States of America ("**USA**") and had appointed a distributor in Hong Kong and the USA. The Company is also pursuing regulatory authorisation for the COVID-19 Antibody Test Kits in certain other jurisdictions.

4. Are you in talks of possible orders of test kits from interested parties?

Company's response: As disclosed in the announcement on 22 April 2020, the Company is actively developing the market for the COVID-19 Antibody Test Kits in Singapore, the Philippines, the European Union as well as the USA. The Company will consider and evaluate the suitability of the various potential distributors and make the appropriate announcements as and when any definitive agreement for the distribution of its COVID-19 Antibody Test Kits has been entered into.

5. What's the profit margin of the test kits? How do you see this impact on the revenue/profit of this financial year?

Company's response: The Company believes that information in relation to the profit margin of the COVID-19 Antibody Test Kits is commercially sensitive.

The COVID-19 Antibody Test Kits is likely to contribute positively to the revenue of the Company for the current financial year ending 31 December 2020 ("**FY2020**"). However, the Company is unable to quantify the financial impact as the Company is unable to ascertain the sales volume for FY2020 and policies in relation to testing or detection of the Novel Coronavirus 2019 may change in response to developments in the COVID-19 situation which is evolving rapidly.

Questions from SIAS

1. On 30 March 2020, the company announced that it had entered into a manufacturer agreement with a diagnostic kit manufacturer to customise and manufacture the Company's rapid test kits for the detection of the Novel Coronavirus 2019 (the "COVID-19 Rapid Test Kits").

In the following week, the company promptly announced that the approval for use of its test kit by the authorities in the Philippines (1 April 2020) and in the European Union (CE Marking – 6 April).

Following queries by the Singapore Exchange Securities Trading Limited ("SGX-ST"), the company announced, on 9 April 2020, that the manufacturing agreement was signed on 21 March 2020 and the provisional authorisation from Health Sciences Authority was received on 27 March 2020. Product liability insurance coverage for the test kits was obtained on 30 March 2020.

(i) Given that the test kits are manufactured by the Chinese supplier, what is the group's value add to the test kit?

Company's response: The Company believes that such information is commercially sensitive. Given the current COVID-19 situation, the market for COVID-19 test kits is immensely competitive with a diverse range of test kits offered by competitors such as medical device distributors, clinical laboratories, biotechnology companies etc. The disclosure of such information may negatively impact the competitive strength of the Company.

(ii) In particular, do the test kits make use of the group's cell enrichment technologies and systems?

Company's response: The Company's COVID-19 Antibody Test Kits does not make use of the Company's patented technology which separate and enrich wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood.

The causative agent of COVID-19 pandemic is a virus named SARS-CoV-2. There are generally 4 methods to identify the causative agent of a viral disease, one of which is the detection of meaningful immune response to the virus by immunoassays (often called serology test). The Lateral Flow Assay ("**LFA**") used by the Company's COVID-19 Antibody Test Kits is one of these such assays. The LFA technology used by the Company's COVID-19 Antibody Test Kits is not new and has been largely deployed in several past pandemics.

2. As noted in the annual report, the unique selling point of the group's ClearCell® FX1 System is its purpose-built retrieval of circulating tumour cells ("CTCs") from the blood sample with the group's patented technology. This could be integrated with other downstream analytical equipment to develop various laboratory developed tests ("LDTs") or laboratory assays for cancer diagnostics.

Currently, the LDTs are yet to be clinically approved (page 7 of the annual report).

(i) Would management update shareholders on the roadmap and the progress made in obtaining clinical approval for its LDTs?

Company's response: As mentioned on pages 6 and 7 of the Company's FY2019 annual report, one of the Company's laboratory partners in China — Hunan Agen Lab has announced the commercial launch of 2 LDTs, one is used to detect CTCs and the other is used to test the status of PD-L1 in cancer patients, in China.

With a total of 6 partnerships to develop LDTs in China, Singapore and Japan, the Company also announced on 28 February 2020 plans to develop its proprietary cancer diagnostic solutions using Biolidics' proprietary technology at LC-Bio's medical laboratory (杭州链康医学检验实验室有限公司) in Hangzhou, China.

The Company will make the appropriate announcements as and when there are material developments in relation to the LDTs and progress of its proprietary cancer diagnostic solutions.

3. On 9 April 2020, the company posted on SGXNet its response to queries raised by the SGX-ST from 1 April 2020 to 8 April 2020. In particular, Question 8 asked about the "financial impact of these developments [the approval and launch of the COVID-19 Rapid test kits]".

The response provided by the company was:

"The Company is not able to ascertain the financial impact of these developments at the time of making the announcement as it has not received any firm orders for the test kits nor commenced manufacturing of the test kits." However, an article published by Forbes on 9 April at 5:26 EDT titled "Antibody Test For COVID-19 Could Help To Control Virus Spread, Says Singapore Medtech Firm1", the company's chief operating officer was quoted as saying "The first batch of test kits are on the plane from China to Singapore as we speak".

In addition, the chairman reportedly provided an estimate of commissioning roughly two million COVID-19 test kits in the next two months from its Nanjing-based producer. The chairman was attributed with the following as well: ""In terms of production, we are only essentially limited by our capital". Forbes also reported that the company will be temporarily reallocating resources meant for its cancer business to fund production of the test kits.

(i) Would the company clarify if the estimate of "commissioning roughly two million COVID-19 test kits in the next two months" could be interpreted as a projection by management?

Company's response: The Company would like to clarify that the query 'What is the financial impact of these developments on the Company?' was raised by SGX on 1 April 2020 in relation to the announcement on 30 March 2020 in relation to the manufacturer agreement and HSA provisional authorisation (the "Announcement"). The Company was not able to ascertain the financial impact of these developments at the time of making the Announcement as it has not received any firm orders for the COVID-19 Antibody Test Kits nor commenced manufacturing of the test kits.

Yee Pinh Jeremy ("**Jeremy**") (Non-Executive Non-Independent Chairman), Leong Man Chun (Interim Chief Executive Officer), Wang Qingyin (Chief Operating Officer) and Alex Tan (Investor and Public Relations Consultant) attended the interview with Forbes on 7 April 2020. The Company had placed an order for the COVID-19 Antibody Test Kits after obtaining the provisional authorisation from HSA and procuring the product liability insurance. As at 7 April 2020 the first batch was in the process of being delivered to the Company.

The remark "estimate of commissioning roughly two million COVID-19 Antibody Test Kits" was referring to the intended build-up in inventory in anticipation of orders for the test kits and not firm orders. As such, the Company would like to clarify that the statement should not be interpreted as a projection by management. The decision on the order volume by the Company in the next two months will be dependent on the sales volume as well as availability of capital and human resources. Given the current COVID-19 situation, the Company will be temporarily reallocating its resources to focus on the COVID-19 Antibody Test Kits to fulfil demand for test kits.

(ii) Would the board be reviewing why the company has given very different responses to Forbes and to SGX-ST?

Company's response: Please refer to our response to Question 3(i).

(iii) Would the board be reviewing the group's communication policies and practices so as to avoid any selective disclosure?

Company's response: As set out in the Corporate Governance section of the Company's annual report, the Company does not practice selective disclosure. The Company is committed to making timely, full and accurate disclosures to shareholders and the public. All information on the Company's new initiatives which would be likely to materially affect the price or value of the Company's shares will be promptly disseminated via SGXNET to ensure fair communication with Shareholders.

For more information about the Company's COVID-19 Antibody Test Kits, please refer to https://www.biolidics.com/2019-ncov-igg-igm-antibody-detection-kit.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
26 April 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.